hotspot -WSS

hotspot

author：entertainment 2025-09-30 18:17:17 - browse：15

Adam's take main illustration — Molly Ferguson/STAT

Shares of Apellis Pharmaceuticals are rebounding, driven by a growing belief among some investors that the serious safety issue that has derailed Syfovre, the company’s eye disease treatment, is receding.

Declaring the crisis over is premature, but that could change with more uneventful weeks. Apellis has been a takeout target before, and may be again, at an acquisition price nearly twice its current market value.

Apellis shares rose 32% last week, with most of the gains coming Friday on heavy trading volume. The reason: There have been no new cases of retinal occlusive vasculitis, or ROV, reported in people receiving injections of Syfovre.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： AI can decode, harness the power of the humane immune system

WSS

Senators: Long

Chan Zuckerberg Biohub Chicago to focus on inflammation

Phenylephrine and the overlooked value of the placebo effect

Why are Kaiser Permanente staff considering a strike?

Medical student insurance fails on mental health care coverage

AI can decode, harness the power of the humane immune system

hotspot

hotspot

knowledge

Continuity nursing helped my family in our darkest PICU moments

Chan Zuckerberg Biohub Chicago to focus on inflammation

What does generative AI mean for health care? We asked experts

Bill would stop addiction treatment from triggering child abuse inquiry

United colonoscopy coverage change 'may cost lives,' doctors say

Senate HELP committee spars over health care workforce policies

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Ukraine and a new approach to mental health in war

ChatGPT in medicine: STAT answers readers' burning questions

Was Amgen transparent enough on FDA's concern on cancer drug?

focus

Phenylephrine and the overlooked value of the placebo effect

Was Amgen transparent enough on FDA's concern on cancer drug?

Intarcia’s device

When women are denied an abortion, their children fare worse than peers

3 questions for the future of Biden's cancer moonshot

Ukraine and a new approach to mental health in war

focus

explore

knowledge

leisure time